84
Participants
Start Date
May 31, 2012
Primary Completion Date
December 12, 2016
Study Completion Date
August 6, 2017
Vivitrol
Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
Employment-based opiate abstinence reinforcement
This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
Usual Care Control
Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
Johns Hopkins Bayview Center for Learning and Health, Baltimore
National Institute on Drug Abuse (NIDA)
NIH
Johns Hopkins University
OTHER